<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="106015">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02065362</url>
  </required_header>
  <id_info>
    <org_study_id>33954: RESIST-NPC</org_study_id>
    <secondary_id>P01CA094237</secondary_id>
    <nct_id>NCT02065362</nct_id>
  </id_info>
  <brief_title>TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC</brief_title>
  <official_title>Administration Of TGF-beta Resistant Cytotoxic T-Lymphocytes to Patients With EBV-positive Nasopharyngeal Carcinoma (RESIST-NPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients have nasopharyngeal carcinoma (NPC). This study is a gene transfer research study
      using special immune cells.

      Most patients with NPC show evidence of infection with the virus that causes infectious
      mononucleosis Epstein Barr virus (EBV) before or at the time of their diagnosis. EBV is
      found in the cancer cells of almost all patients with advanced stage NPC, suggesting that it
      may play a role in causing the disease. The cancer cells infected by EBV are able to hide
      from the body's immune system and escape destruction. We want to see if special white blood
      cells, called T cells, that have been trained to recognize and kill special parts of EBV
      infected cells can survive in patient's blood and affect the tumor.

      We already have given EBV-specific cytotoxic T cells to 30 patients with active NPC and have
      seen anti-tumor activity in 14 of 30 patients. We are now trying to find out if we can
      improve this treatment.

      First, we want to give T cells where more of the cells recognize at least two of the four
      EBV proteins expressed on NPC cells. We call these cells NPC-specific cytotoxic T cells
      (NPC-specific CTLs).

      Second, we found that T cells work better if we add a receptor to the T cells called DNR
      (Dominant Negative Receptor). DNR makes T cells resistant to TGFbeta, a factor secreted by
      cancer cells that helps them escape being killed by the immune system. In this study we will
      therefore place the DNR gene into NPC-specific CTLs (DNR.NPC-specific CTLs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood will be collected from the patient to make LMP/BARF1/EBNA1 (NPC)-specific CTLs. To
      grow NPC-specific CTLs we have to use special cells called antigen-presenting cells, which
      train the patient's T cells to be NPC specific. Antigen presenting cells, so called
      monocytes or dendritic cells, will be grown/isolated from the patient's blood. In addition,
      we use a cell line called K562 as antigen-presenting cells that has had genes put inside it,
      which encourage the patient's T cells to grow. K562 cells are cancer cells. As such, if
      injected they could cause cancer. The cells have been treated with radiation so they cannot
      grow.

      These antigen-presenting cells are coated with a specially produced mixture of LMP, EBNA1
      and BARF protein fragments called peptides. These coated antigen-presenting cells are then
      used to generate the patient's NPC-specific CTLs in the presence of growth factors. To get
      the DNR to attach to the surface of these NPC-specific CTLs, we also inserted the DNR gene
      into the NPC-specific CTL (DNR.NPC-specific CTLs). This is done with a virus called a
      retrovirus that has been made for this study. This virus will carry the DNR gene into the
      cells.

      Once we have made sufficient numbers of DNR.NPC-specific CTLs we will freeze the cells and
      test them to make sure they recognize EBV proteins present in NPC.

      Patients will get treated with two doses of DNR.NPC-specific CTLs. The second dose will be
      given 2 weeks after the first dose.

      The CTLs will be thawed and injected through a central line, or through a vein in the
      patient's arm over 1 to 10 minutes. Patients will be followed in the clinic after the
      injection for 1 to 4 hours.

      All of the treatments will be given by the Center for Cell and Gene Therapy at Texas
      Children's Hospital or Houston Methodist Hospital.

      Medical tests before treatment:

      Before being treated, the patient will receive a series of standard medical tests:

      Physical exam Imaging Study Blood tests to measure blood cells, kidney and liver function
      Measurements of the tumor by routine imaging studies. We will use the imaging study that was
      used before to follow the patient's tumor: Computer Tomogram (CT), Magnetic Resonance
      Imaging (MRI), or Positron Emission Tomography (PET/CT)

      Medical tests during and after treatment:

      The patient will receive standard medical tests when they are getting the infusions and
      after:

      Physical exams Blood tests to measure blood cells, kidney and liver function Imaging study 8
      weeks after the 1st CTL infusion

      To learn more about the way the DNR.NPC-specific CTL are working and how long they last in
      the body, an extra 60ml or 3ml/kg of body weight of blood (whichever is less) will be taken
      on the day of the T-cell infusion (before and at the end of the T-cell infusion), 1, 2, 3,
      4. 6, and 8 weeks after the T-cell infusion and every 3 months for 1 year, every 6 months
      for 4 years, then yearly for a total of 15 years. One additional blood sample might be drawn
      3 to 4 days post the 1st T-cell infusion; this is optional. This volume is considered safe,
      but may be decreased if the patient is anemic. In addition to the blood tests, the patient
      will receive 2 imaging studies as stated above.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2032</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects with a dose limiting toxicity</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine the safety of escalating doses of 2 intravenous injections of autologous TGFbeta-resistant NPC-specific cytotoxic T-lymphocytes (CTL) in patients with EBV-positive nasopharyngeal carcinoma (NPC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of T cells in the blood after the infusions</measure>
    <time_frame>15 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine the survival and the immune function of TGFbeta-resistant NPC specific CTL.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with a response to the T cells</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the anti-viral and anti-tumor effects of TGFbeta-resistant NPC specific CTL.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>EBV-positive Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>DNR.NPC-specific CTLs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 2 injections of DNR.NPC-specific CTLS, 14 days apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNR.NPC-specific CTLs</intervention_name>
    <description>Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:
Dose Level 1:
Day 0 2x10^7 cells/m^2
Day 14 2x10^7 cells/m^2
Dose Level 2:
Day 0 2x10^7 cells/m^2
Day 14 1x10^8 cells/m^2
Dose Level 3:
Day 0 1x10^8 cells/m^2
Day 14 2x10^8 cells/m^2</description>
    <arm_group_label>DNR.NPC-specific CTLs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The patient must meet the following eligibility inclusion criteria at the time of
        PROCUREMENT:

          -  Nasopharyngeal Carcinoma in first or subsequent relapse or with primary refractory
             disease

          -  EBV positive tumor

          -  Informed consent explained to, understood by and signed by patient/guardian.
             Patient/guardian given copy of informed consent

        The patient must meet the following eligibility criteria to be included for TREATMENT:

          -  Nasopharyngeal Carcinoma in first or subsequent relapse or with primary refractory
             disease

          -  EBV positive tumor

          -  Patients with life expectancy greater than or equal to 6 weeks

          -  Bilirubin less than or equal to 3x upper limit of normal

          -  AST less than or equal to 5x upper limit of normal

          -  Hgb &gt; 8.0g/dl

          -  Creatinine less than or equal to  2x upper limit of normal for age

          -  Pulse oximetry of &gt; 90% on room air

          -  Off investigational therapy for 4 weeks prior to study entry

          -  Karnofsky or Lansky score of greater than or equal to 50%

          -  Sexually active patients must be willing to utilize one of the more effective birth
             control methods during the study and for 6 months after the study is concluded. The
             male partner should use a condom.

          -  Informed consent explained to, understood by and signed by patient/guardian.
             Patient/guardian given copy of informed consent.

        Exclusion Criteria:

        At time of Procurement:

        â€¢Known HIV positivity

        At time of Treatment:

          -  Pregnant or lactating

          -  Severe intercurrent infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stepehen MG Gottschalk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine/Texas Children's Hospital /Houston Methodist Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen MG Gottschalk, MD</last_name>
    <phone>832-824-4179</phone>
    <email>smgottsc@txch.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Perera</last_name>
    <phone>832-824-4594</phone>
    <email>csperera@txch.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Gottschalk, MD</last_name>
      <phone>832-824-4179</phone>
      <email>smgottsc@txch.org</email>
    </contact>
    <contact_backup>
      <last_name>Chrystal U Louis, MD</last_name>
      <phone>832-824-4809</phone>
      <email>culouis@txch.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Gottschalk, MD</last_name>
      <phone>832-824-4179</phone>
      <email>smgottsc@txch.org</email>
    </contact>
    <contact_backup>
      <last_name>Chrystal U Louis, MD</last_name>
      <phone>832-824-4809</phone>
      <email>culouis@txch.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 14, 2014</lastchanged_date>
  <firstreceived_date>February 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Stephen Gottschalk</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>EBV positive</keyword>
  <keyword>TGFbeta</keyword>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>cytotoxic T lymphocytes</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
